ChemoCentryx: A Biotech Stock Well Worth the Risk Posted byMarketBeat Staff May 9, 2022 Leave a comment on ChemoCentryx: A Biotech Stock Well Worth the Risk In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point…